Stoke Therapeutics, Inc.: Stoke Therapeutics Receives Authorization to Initiate a Phase 1/2 Study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in the United Kingdom
- Company advancing second TANGO ASO into the clinic - - STK-002 has the potential to be the first disease-modifying therapy to address the root cause of ADOA, the most common inherited optic nerve
United Kingdom United States Barry Ticho Eric Rojas Company Annual Report On Form Augmentation Of Nuclear Gene Output
Source: finanznachrichten.de